FDA'S PETITION REQUIREMENT FOR SEC. 515(b) RECLASSIFICATION REQUESTS IS CONTRARY TO FD&C ACT, LAWYER SAYS; FDA NOTES RULE WAS FINALIZED WITHOUT NEGATIVE COMMENT
This article was originally published in The Gray Sheet
Executive Summary
FDA goes beyond the statutory intent of the Food, Drug and Cosmetic Act in requiring that reclassification requests submitted in response to section 515(b) calls for premarket approval applications be in the form of petitions, attorney Larry Pilot (Washington, D.C. office of McKenna & Cuneo) says in a June 12 letter to the agency. "Although the term `request' is not defined in the Act, [FDA's] requirement for a `petition' clearly goes beyond the meaning that this statutory provision can bear," Pilot says.
You may also be interested in...
Despite 'Remarkable' ROI On Women’s Health Investments, Money Still Lacking
Recent US government initiatives and growing investor interest are important for developing female-specific therapeutics, but funding is not yet where it should be.
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues in an interview with Scrip.
Ratio Therapeutics On BMS Investment, Radiopharma R&D Trends, AI Use
The CEO and CSO of radiopharmaceutical company Ratio Therapeutics, which now has Bristol Myers Squibb as an investor, talk about Ratio’s R&D platforms, use of AI, an independent FAP-targeted asset and trends in radiopharma research such as combining other modalities like ADCs, in this podcast interview with Scrip